Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment-Reference-Cited by-同舟云学术

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Dowell James A.¹,Marbury Thomas C.²,Smith William B.³,Henkel Tim⁴^ORCID

Affiliation:

1. Pharmacology Development Services, LLC, Collegeville, Pennsylvania, USA

2. Orlando Clinical Research Center, Orlando, Florida, USA

3. Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, Tennessee, USA

4. Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA

Abstract

Taniborbactam, an investigational β-lactamase inhibitor that is active against both serine- and metallo-β-lactamases, is being developed in combination with cefepime to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Anticipating the use of cefepime-taniborbactam in patients with impaired renal function, an open-label, single-dose clinical study was performed to examine the pharmacokinetics of both drugs in subjects with various degrees of renal function.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Venatorx Pharmaceuticals

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00253-22

Reference22 articles.

1. Daigle DM, Burns CJ. 2018. Kinetic mechanism & parameters of inhibition of KPC-2, CTX-M15, p99 AmpC and VIM-2 by the β-lactamase inhibitor VNRX-5133, abstr O0606. Abstr 28th Eur Cong Clin Microbiol Infect Dis, Madrid, Spain.

2. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

3. Hamrick J, Chatwin C, John K, Pevear D, Burns C, Xerri L. 2018. The ability of broad-spectrum beta-lactamase inhibitor VNRX-5133 to restore bactericidal activity of cefepime in Enterobacteriaceae- and P aeruginosa-expressing Ambler class A, B, C and D enzymes is demonstrated using time-kill kinetics, abstr P1545. Abstr 28th Eur Cong Clin Microbiol Infect Dis, Madrid, Spain.

4. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

5. Maxipime (cefepime hydrochloride). 2012. Hospira Inc. Lake Forest IL.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydroxyhexylitaconic acids as potent IMP-type metallo-β-lactamase inhibitors for controlling carbapenem resistance in Enterobacterales;Microbiology Spectrum;2024-02-05

2. Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States;Antimicrobial Agents and Chemotherapy;2023-11-15

3. Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa;Pharmaceuticals;2023-08-30

4. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations;Saudi Pharmaceutical Journal;2023-08

5. Novel Antimicrobial Agents for Gram-Negative Pathogens;Antibiotics;2023-04-16